: Intensive chemotherapy with autologous stem cell transplantatio

: Intensive selleckchem chemotherapy with autologous stem cell transplantation in ovarian cancers: analysis of 67 patients treated at the Paoli-Calmettes Institute and a review of the literature. Bull Cancer 1997, 9:869–876. 29. Cure H, Battista C, Guastalla JP, Fabbro M, Tubiana-Mathieu N, Bourgeois H, et al.: Phase III Randomized Trial of High-Dose Chemotherapy (HDC) and Peripheral Blood Stem Cell (PBSC) Support as Consolidation in Patients (pts) with Responsive Low-Burden Advanced Ovarian Cancer (AOC): Preliminary Results of a GINECO/FNCLCC/SFGM-TC Study. Proc Am Soc Clin Oncol 2001.,20(abstr 815): 30. Legros M, Dauplat J,

Fleury J, Cure H, Suzanne F, Chassagne J, et al.: High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. J Clin Oncol 1997, JIB04 datasheet 15:1302–1308.PubMed 31. Stiff PJ, Bayer R, Kerger C, Potkul RK, Malhotra D, Peace DJ, et al.: High-dose chemotherapy with autologous transplantation

for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997, 15:13092–1317. 32. Stiff PJ, Shpall EJ, Liu PY, Wilczynski SP, Callander NS, Scudder SA, et al.: Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study. Gynecol Oncol 2004, 94:98–106.PubMedCrossRef 33. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al.: BRCA1 and BRCA2 mutations account for a large proportion of ovarian BTK inhibitor nmr carcinoma cases. Cancer 2005, 104:2807–2816.PubMedCrossRef 34. Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, et al.: Clinicopathologic Tau-protein kinase features of BRCA-linked and sporadic ovarian cancer. JAMA 2000, 283:2260–2265.PubMedCrossRef 35. Vencken PM, Kriege M, Hoogwerf D, Beugelink S, van der Burg ME, Hooning MJ, et al.: Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with

sporadic ovarian cancer patients. Ann Oncol 2011, 22:1346–1352.PubMedCrossRef 36. Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, et al.: “”BRCAness”" syndrome in ovarian cancer: a case–control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008, 26:5530–5536.PubMedCrossRef 37. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, et al.: Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010, 28:3555–3561.PubMedCrossRef 38. Bast RC Jr, Mills GB: Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol 2010, 28:3545–3548.PubMedCrossRef 39. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>